5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
This study is being done because both 5-azacytidine and nivolumab can influence the immune
system's response to HPV-associated head and neck cancer, and we wish to evaluate whether
taking 5-azacytidine will make HPV-associated head and neck cancer more sensitive to
treatment with nivolumab.
5-Azacytidine (5-AZA) is a chemotherapy, and nivolumab is an immunotherapy. Both drugs are
approved for use in the US by the Food and Drug Administration (FDA) for use in the treatment
of different types of cancer, and nivolumab is approved for use in head and neck cancer that
has previously been treated with chemotherapy. Because they are not approved to be used
together in HPV-associated head and neck cancer, these drugs are considered experimental in
this study. For this study, the drugs will be used either together or separately.